Abstract
Introduction
Nausea and vomiting are distressing symptoms affecting between 20% and 70% of patients with advanced cancer. Methotrimeprazine is a phenothiazine antipsychotic used in palliative care for the management of terminal agitation and nausea/vomiting but there is only anecdotal evidence to support its use in palliative care.
Aim
To establish whether nausea/vomiting in palliative care patients is improved by the administration of low-dose methotrimeprazine.
Methods
Patients with advanced malignancy were entered at different treatment levels according to symptom severity. The dose was altered according to response (minimum dose 6.25 mg daily po, maximum 25 mg by 24-h subcutaneous infusion). Symptoms and side effects were recorded daily from 0 (baseline) to day 5 using a four-point scale. Any improvement in nausea/vomiting score was taken as a response.
Results
Sixty-five patients were entered. The cause of nausea and vomiting was multifactorial in the majority of patients, 35/65 (54%). As expected in a study of patients with poor performance status, the attrition rate was high. Of 53 patients evaluable for response at day 2, 33 (62%) showed some improvement in nausea or vomiting. At day 5, improvement was seen in 20/34 (58%). There was no significant change in “side effects” from baseline with time.
Conclusion
These results suggest that methotrimeprazine has antiemetic activity.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Twycross R, Back I (1998) Nausea and vomiting in advanced cancer. Eur J Palliat Care 5(2):39–45
Twycross RG, Barkby GD, Hallwood PM (1997) The use of low dose methotrimeprazine (methotrimeprazine) in the management of nausea and vomiting. Prog Palliat Care 5(2):49–53
Oliver DJ (1985) The use of methotrimeprazine in terminal care. Br J Clin Pract 39(9):339–340
Higi M, Niederle N, Bierbaum W et al (1980) Pronounced antiemetic activity of the antipsychotic drug methotrimeprazine (L) in patients receiving cancer chemotherapy. J Cancer Res Clin Oncol 97:81–86
Vetter V, Beck JD (1995) The prevention of nausea and vomiting in children on chemotherapy. Monschr Kinderheilkd 143:1242–1246
Dobkin AB, Purkin N (1960) Double blind study of phenothiazines used in pre-anaesthetic medication; a clinical evaluation of promethazine (Phenergan), promazine (Sparine), prochlorperazine (Stemetil) and methotrimeprazine (Nozinan). Can Anaesth Soc J 7:158–165
Lichter I (1993) Results of antiemetic management in terminal illness. J Palliat Care 9 (2):19–21
Edmonds PM, Stuttaford JM, Penny J et al (1998) Do hospital palliative care teams improve symptom control? Use of a modified STAS as an evaluation tool. Palliat Med 12 (5):345–351
Critchley P, Plach N, Grantham M et al (2001) Efficacy of Haloperidol in the treatment of nausea and vomiting in the palliative patient: a systematic review. J Pain Symptom Manage 22(2):631–633
Mystakidou K, Befon S, Liossi C, Vlachos L (1998) Comparison of the efficacy and safety of tropisetron, metoclopramide, and chlorpromazine in the treatment of emesis associated with far advanced cancer. Cancer 83(6):1214–1223
Bruera E, Belzile M, Neumann C et al (2000) A double blind crossover study of controlled release metoclopramide and placebo for the chronic nausea and dyspepsia of advanced cancer. J Pain Symptom Manage 19(6):427–435
Corli O, Cozzolino A, Battaiotto L (1995) Effectiveness of levosulpiride versus metoclopramide for nausea and vomiting in advanced cancer patients: a double-blind, randomized, crossover study. J Pain Symptom Manage 10(7):521–526
Bruera E, MacEachern TJ, Spachynski KA et al (1994) Comparison of the efficacy, safety and pharmacokinetics of controlled release and immediate release metoclopramide for the management of chronic nausea in patients with advanced cancer. Cancer 74(12):3204–3211
Bruera E, Sefert L, Watanabe S et al (1996) Chronic nausea in advanced cancer patients: a retrospective assessment of a metoclopramide-based antiemetic regimen. J Pain Symptom Manage 11(3):147–153
Nelson K, Walsh D (1993) Metoclopramide in anorexia caused by cancer-associated dyspepsia syndrome (CADS). J Palliat Care 9(2):14–18
Bruera E, Brenneis C, Michaud M et al (1987) Continuous sc infusion for treatment of narcotic bowel syndrome. Cancer Treat Rep 71(11):1121–1122
Bruera E, MacDonald N, Brenneis C et al (1986) Metoclopramide infusion with a disposable portable pump. Ann Intern Med 104(6):896
Wilson J, Plourde J-Y, Marshall D et al (2002) Long-term safety and clinical effectiveness of controlled-release metoclopramide in cancer-associated dyspepsia syndrome: a multicentre evaluation. J Palliat Care 18(2):84–91
Glare P, Pereira G, Kristjanson L, Stockler M (2004) Systematic review of the efficacy of antiemetics in the treatment of nausea in patients with far-advanced cancer. Support Care Cancer 12:432–440
Jordhoy M, Kaasa S, Fayers P et al (1999) Challenges in palliative care research: recruitment, attrition and compliance: experience from a randomised controlled trial. Palliat Med 13:299–310
Dickman A, Littlewood C, Varga J (2003) The syringe driver-continuous subcutaneous infusions in palliative care. Oxford University Press, Oxford, UK
Acknowledgements
The interim analysis of this study was presented at the EAPC Research Network Conference in Lyon, France, May 2002.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Kennett, A., Hardy, J., Shah, S. et al. An open study of methotrimeprazine in the management of nausea and vomiting in patients with advanced cancer. Support Care Cancer 13, 715–721 (2005). https://doi.org/10.1007/s00520-004-0768-1
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00520-004-0768-1